Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:18:50 EDT Tue 01 Jul 2025
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.1110.16·111.369.0110.87+0.200.26,600.5727,94951,808110.61  111.44  109.88119.95  66.0119:52:11Jun 2515 min RT 2¢

Recent Trades - Last 10 of 51808
Time ETExPriceChangeVolume
19:52:11Q111.230.5654
19:52:11Q111.250.58400
19:51:00Q111.230.5636
19:49:21Q111.20060.53064
19:49:16Q111.120.456
19:49:16Q111.200.53100
19:49:16Q111.200.5399
19:48:52Q111.180.5190
19:48:52Q111.200.53750
19:43:34Q111.170.5036

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-25 07:00U:GILDNews ReleaseGilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
2025-06-24 09:25U:GILDNews ReleaseGilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion
2025-06-18 14:49U:GILDNews ReleaseYeztugo(TM) (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
2025-06-05 09:20U:GILDNews ReleaseGilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
2025-06-01 08:00U:GILDNews ReleaseKite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta(TM) in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
2025-05-31 08:00U:GILDNews ReleaseTrodelvy(TM) Plus Keytruda(TM) Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
2025-05-30 09:35U:GILDNews ReleaseGilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden
2025-05-23 08:30U:GILDNews ReleaseASCENT-03: Trodelvy(TM) Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
2025-05-20 09:02U:GILDNews ReleaseTomas Cihlar, Gilead Sciences, Named to TIME's List of 100 Most Influential People in the World for HIV Research
2025-05-15 16:15U:GILDNews ReleaseGilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
2025-05-15 09:27U:GILDNews ReleaseGilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories
2025-05-13 08:51U:GILDNews ReleaseThe 2024 Responsible Business and Impact Report Shares How Gilead Sciences Is Driving Change
2025-05-08 09:02U:GILDNews ReleaseEarth Day Focus for Gilead Sciences - Every Action Has an Impact
2025-05-07 02:30U:GILDNews ReleaseFinal Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
2025-05-07 02:15U:GILDNews ReleaseGilead's Livdelzi(TM) (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
2025-05-06 08:41U:GILDNews ReleaseFighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
2025-04-29 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2025-04-29 08:36U:GILDNews ReleaseGilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV's Impact in the United States
2025-04-29 08:30U:GILDNews ReleaseGilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
2025-04-24 16:02U:GILDNews ReleaseGilead Sciences Announces First Quarter 2025 Financial Results